Magle Chemoswed Holding AB ("Magle Group" or the "Company") has today acquired all shares in pK Biotech ApS ("pK Biotech") and its subsidiary pK Chemicals A/S ("pK Chemicals") in accordance with the agreements announced by press releases on 17 June 2024 and on 28 June 2024. The purchase price for all shares in pK Biotech has been paid in the form of a seller promissory note of approximately SEK 240 million, which shall be offset against 7,200,000 newly issued shares in Magle Group (the "Consideration Shares").
Magle Group has today acquired all shares in pK Biotech and paid the purchase price to the seller PRS1 ApS in the form of a seller promissory note. The seller promissory note does not carry interest and shall be offset against 7,200,000 newly issued shares in Magle Group. The Board of Directors in Magle Group intends to convene a shareholders' meeting to resolve on the new issue of the Consideration Shares. Completion of the set-off issue requires clearance by the Swedish Inspectorate of Strategic Products of the Seller's subscription of the Consideration Shares under the Swedish Screening of Foreign Direct Investment Act. The shareholders' meeting that will resolve on the set-off issue is expected to take place during the third quarter of 2024. Notice to the shareholders' meeting will be published separately.
pK Biotech is a holding company and pK Chemicals is a wholly owned operating company. pK Chemicals, headquartered in Denmark, is a distinguished player in the global pharmaceutical and medico sectors, renowned for its specialization in the production of technical Dextran, Dextran Derivatives, and a broad spectrum of customized products. Beyond its product offerings, pK Chemicals' expertise extends to providing comprehensive contract manufacturing services. These services range from assisting in the initiation of biopolymer development to optimizing processes for intermediates, showcasing pK Chemical's versatility and technical proficiency, as well as capabilities in producing specialized products for the healthcare sectors.
Advisors
Vator Securities AB is the financial advisor and Advokatfirman Schjødt is the legal advisor to Magle Group in connection with the transaction.
Contacts
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed - a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept - an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
